Joel Batten

Joel Batten joined Veru as its Executive Vice President and General Manager, Infectious Disease Franchise in May 2022. Mr. Batten is responsible for directing Veru’s newly formed U.S. Infectious Disease Franchise, in addition to developing and leading all aspects of the Company’s U.S. go-to-market strategy for sabizabulin for the treatment of COVID-19.

Most recently, Mr. Batten served as Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North America, where he was in charge of the Synagis business (approximately $600M in gross revenue) and led a team of over 160 employees. Furthermore, Mr. Batten managed the sales and marketing efforts for the RSV Franchise, as well as the strategy for market access, distribution, and patient access services. Prior to Sobi, Mr. Batten spent almost 20 years in various positions of increasing responsibility at AstraZeneca/MedImmune and Sanofi Aventis in multiple infectious disease franchises, including commercial infrastructure build-out, product launch, sales management, marketing, public health sales, and government affairs.